Tenet Wealth Partners LLC Purchases New Stake in Eli Lilly and Company $LLY

Key Points

• Tenet Wealth Partners purchased 1,402 Eli Lilly shares worth approximately $1.68 million, making LLY its 19th-largest holding at 1.2% of the portfolio. Institutional investors collectively own 82.53% of the company.
• Analysts remain broadly bullish, with 24 Buy ratings and a consensus “Moderate Buy” rating; the average price target is $1,292.18 versus a recent share price of about $1,147.
• Eli Lilly reported strong quarterly results, including $8.38 adjusted EPS and $22.97 billion in revenue, up 47.7% year over year. The company also declared a $1.73 quarterly dividend, while insiders sold shares under pre-arranged trading plans.

Tenet Wealth Partners LLC bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,402 shares of the company's stock, valued at approximately $1,679,000. Eli Lilly and Company makes up approximately 1.2% of Tenet Wealth Partners LLC's holdings, making the stock its 19th largest holding.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Norges Bank acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $12,976,634,000. Bank of America Corp DE acquired a new stake in Eli Lilly and Company in the 2nd quarter worth about $13,522,666,000. J. Stern & Co. LLP grew its stake in shares of Eli Lilly and Company by 46,191.3% during the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company's stock valued at $4,047,245,000 after buying an additional 4,038,502 shares during the period. Jupiter Topco LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $4,667,180,000. Finally, Cardano Risk Management B.V. increased its position in shares of Eli Lilly and Company by 876.1% in the fourth quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company's stock worth $2,552,419,000 after acquiring an additional 2,131,734 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. The Goldman Sachs Group reissued a "buy" rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a "buy" rating in a report on Friday, August 7th. Wolfe Research reissued an "outperform" rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a report on Thursday, May 21st. Jefferies Financial Group increased their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a "buy" rating in a report on Tuesday, June 9th. Finally, Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,292.18.

Eli Lilly and Company Stock Down 0.2%

Shares of LLY stock opened at $1,147.06 on Tuesday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock's 50 day simple moving average is $1,190.13 and its 200 day simple moving average is $1,070.66. The company has a market capitalization of $1.08 trillion, a price-to-earnings ratio of 38.49, a PEG ratio of 1.42 and a beta of 0.50. Eli Lilly and Company has a twelve month low of $712.05 and a twelve month high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business had revenue of $22.97 billion during the quarter, compared to analysts' expectations of $20.82 billion. During the same quarter in the previous year, the firm earned $6.31 EPS. The firm's revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts predict that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company's dividend payout ratio is currently 23.22%.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by company insiders.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Large obesity-drug opportunity: J.P. Morgan estimates Eli Lilly could benefit from a roughly $100 billion incretin opportunity. Zepbound and Mounjaro continue to provide substantial growth, while next-generation therapies could extend the company’s expansion beyond its current products. Eli Lilly’s $100B incretin opportunity: Is more upside coming?
• Positive Sentiment: Acquisitions could diversify future growth: Recent deals are being viewed as an effort to build Eli Lilly’s long-term pipeline and reduce reliance on today’s blockbuster GLP-1 medicines. The strategy could support additional revenue streams as the company’s core drugs mature. Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?
• Positive Sentiment: Institutional buying signals confidence: Citadel Advisors and Duquesne Family Office reportedly purchased LLY shares during the second quarter, potentially viewing an earlier pullback as an attractive entry point. Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock
• Neutral Sentiment: Analyst and Zacks comparisons portray Lilly as the higher-growth choice versus Johnson & Johnson, but also note that investors must accept greater product-concentration and execution risks. Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?
• Negative Sentiment: Competition and patent limits remain key overhangs: Mounjaro, Zepbound and other leading products face increasing competition, while their patent protection is time-limited. Those concerns may be contributing to caution after the stock’s strong run, particularly given its premium earnings multiple. Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.